Anti-BCMA CAR T-Cell Therapy Approaches 80% Response Rate in Multiple Myeloma – Targeted Oncology
|
Anti-BCMA CAR T-Cell Therapy Approaches 80% Response Rate in Multiple Myeloma
Targeted Oncology An investigational anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy demonstrated an objective response rate (ORR) of 78% in patients with relapsed/refractory multiple myeloma, according to interim findings of a phase … |
